1. Home
  2. INVZ vs ADCT Comparison

INVZ vs ADCT Comparison

Compare INVZ & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVZ
  • ADCT
  • Stock Information
  • Founded
  • INVZ 2016
  • ADCT 2011
  • Country
  • INVZ Israel
  • ADCT Switzerland
  • Employees
  • INVZ N/A
  • ADCT N/A
  • Industry
  • INVZ Auto Parts:O.E.M.
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • INVZ Consumer Discretionary
  • ADCT Health Care
  • Exchange
  • INVZ Nasdaq
  • ADCT Nasdaq
  • Market Cap
  • INVZ 369.4M
  • ADCT 380.2M
  • IPO Year
  • INVZ N/A
  • ADCT 2020
  • Fundamental
  • Price
  • INVZ $2.36
  • ADCT $4.43
  • Analyst Decision
  • INVZ Strong Buy
  • ADCT Strong Buy
  • Analyst Count
  • INVZ 4
  • ADCT 6
  • Target Price
  • INVZ $3.27
  • ADCT $7.80
  • AVG Volume (30 Days)
  • INVZ 9.6M
  • ADCT 1.0M
  • Earning Date
  • INVZ 11-12-2025
  • ADCT 11-06-2025
  • Dividend Yield
  • INVZ N/A
  • ADCT N/A
  • EPS Growth
  • INVZ N/A
  • ADCT N/A
  • EPS
  • INVZ N/A
  • ADCT N/A
  • Revenue
  • INVZ $37,684,000.00
  • ADCT $77,246,000.00
  • Revenue This Year
  • INVZ $153.22
  • ADCT $13.10
  • Revenue Next Year
  • INVZ $91.44
  • ADCT $6.23
  • P/E Ratio
  • INVZ N/A
  • ADCT N/A
  • Revenue Growth
  • INVZ 17.32
  • ADCT 15.73
  • 52 Week Low
  • INVZ $0.45
  • ADCT $1.05
  • 52 Week High
  • INVZ $3.14
  • ADCT $4.67
  • Technical
  • Relative Strength Index (RSI)
  • INVZ 69.27
  • ADCT 76.71
  • Support Level
  • INVZ $1.66
  • ADCT $3.37
  • Resistance Level
  • INVZ $2.21
  • ADCT $4.07
  • Average True Range (ATR)
  • INVZ 0.17
  • ADCT 0.23
  • MACD
  • INVZ 0.05
  • ADCT 0.08
  • Stochastic Oscillator
  • INVZ 85.37
  • ADCT 82.93

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: